Soft Tissue Allografts Market Size, Share & Trends Analysis Report By Type (Cartilage Allograft, Tendon Allograft, Meniscus Allograft, Dental Allograft, Other Types), By Application (Orthopedic, Dentistry, Wound Care, Other Applications), By End User (Hospitals, Aesthetic Centers, Orthopedic Clinics, Dental Clinics, Other End Users) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Market Overview

The global soft tissue allografts market size was worth USD 3,290 million in 2021, and it is estimated to reach an expected value of USD 5995 million by 2030, registering a CAGR of 6.9% during the forecast period (2022-2030).

The major factors propelling the growth of the studied market comprise the rising prevalence of joints and bone disorders worldwide, an increasing geriatric population, technological advancements in tissue replacement, and an increasing number of injuries and accidents. Furthermore, the growing geriatric population worldwide is another factor contributing to the growth of the global cartilage repair/regeneration market. In addition, the high demand for allografts for soft tissue reconstruction is due to the need for stable knees that help protect from further injury to the ligaments and restore knee function. In addition, allografts offer many benefits compared to autografts in musculoskeletal reconstruction, like the reconstruction of the internal ligament. Osteoarthritis significantly impacts individual patients, resulting in pain and disability, and society. The increasing prevalence of this disease is expected to boost the market in the near future.

Market Dynamics

Global soft tissue allografts market drivers

Growing cases of orthopedics and dentistry related to aging

Globally, there has been an increasing prevalence of orthopedic disorders, leading to disability and negatively impacting people's physical and mental well-being. The market is positively impacted by osteoarthritis, one of the more prevalent types of joint disease that influence people over 65 in both developed and developing nations. Osteoarthritis is recognized by a gradual loss of cartilage in joints, which causes the bones to rub against one another and cause stiffness, pain, and impaired movement.

For instance, according to a study by M. Kloppenburg et al. published in the Osteoarthritis and Cartilage Journal 2020, osteoarthritis is a prevalent rheumatic musculoskeletal condition that afflicted around 303 million people worldwide in 2017. Any joint can be affected, although the hands, knee, hip, and spine are most frequently affected. Osteoarthritis has a significant negative influence on the patient, causing pain and impairment, as well as on society, which is anticipated to increase demand in the near future.

Another factor contributing to the global expansion of the cartilage repair/regeneration market is the expanding elderly population worldwide. For instance, the World Ageing 2019 report estimates that around 703 million people worldwide in 2019 were 65 or older. By 2050, it is predicted that there will be 1.5 billion senior people. Worldwide, the proportion of people 65 and older rose from 6% in 1990 to 9% in 2019. By 2050, 16% is the predicted increase in the percentage. Globally, 1 in 6 persons will be over 65 by 2050, up from 1 in 11 in 2019. This indicates the rising demand for anterior cruciate ligament surgeries, thereby boosting the growth of soft tissue allografts.

Increasing demand for soft tissue allografts in athletics and other sports

 Soft tissue allografts are a vital substitute for reconstructing deficient ligaments, torn menisci, and osteochondral defects during knee surgery. Interest in allografts for soft tissue reconstruction has arisen from the demand to obtain a stable knee with the restoration of function and protection against additional injury. Orthopedic surgeons now frequently employ allografts to treat musculoskeletal disorders, including osteochondral abnormalities in the glenohumeral joint and meniscal deficits in young athletes.

All sports, including top athletics, increase anterior cruciate ligament (ACL) injuries. According to a 2020 article by Rafael A. Buerba referencing sports injuries, ACL injuries can impact a player's long life and other long-term effects, like the emergence of future arthritis. Improved athletic performance is strongly connected with high-intensity training programs, but overtraining also wears down muscles and bones and frequently results in injury. As a result, injuries have become more common among athletes, mainly as a result of overtraining. Athletes now demand speedy recovery and readily available modalities to treat musculoskeletal problems due to the competitive nature of sports. Hence, the demand for soft tissue allografts has been increasing in athletics and other contact sports, which drives the growth of the global soft tissue allografts market.

Global soft tissue allografts market restraint

High cost of treatment

Although the treatments are up-and-coming for treating various disorders involving soft tissue damage, their high cost is among the main barriers preventing their widespread use among patients. In the 2019 article "Patient- and Procedure-Specific Variables Driving Total Direct Costs of Outpatient Anterior Cruciate Ligament Reconstruction(ACLR)," Michael R. Karns, MD stated that the use of an allograft or hybrid graft, longer operating room time, and concurrent meniscus repair were predictors of an increased direct cost. The study concluded that allografts and hybrid grafts were associated with an increased total direct cost. Approximately 25% of meniscal tears are reported to be repaired during ACLR.

The cost of Stravix is a living placental tissue for surgical applications, which retains the native collagen and hyaluronic acid-rich extracellular matrix (ECM), endogenous growth factors, and endogenous cells, including epithelial cells, fibroblasts, and mesenchymal stem cells (MSCs) found in placental tissue. Though this is a highly advanced allograft, the price of Stravix 2/4 CMX/CM at US pharmacies starts at USD 1,883.83 per sheet. This is considerable for many people in developing countries and backward regions. Therefore, due to the high costs of products and procedures, few patients do not undergo these procedures and treatments, which restraints the market's growth.

Global soft tissue allografts market opportunities

Advancements in soft tissue replacement

In recent decades, the field of soft tissue repair has made significant advances. Robotic-assisted technology offers a novel surgical innovation platform for tissue repair and reconstruction. Compared with laparoscopic surgery, surgical robots not only inherit the advantages of laparoscopic surgery but also have other merits. Firstly, a surgical robot wrist joint is much more flexible and can take multiple positions in a 360°dimension to match the surgeon's style during the operation readily. Secondly, the operating arm can intelligently filter out human hand vibration. Thirdly, the display can provide a high-definition 3D view of the operating area.

A growing number of clinical trials study the efficacy of soft allografts and comparisons between xenografts and allografts. The increasing research boosts market growth. According to clinical truials.gov, as of March 15, 2020, 46 studies on soft tissue allografts have been conducted. For instance, in collaboration with Ahmed Mohamed Ibrahim Elkady, Cairo University, Cairo University started a trial in 2020 to evaluate the non-incised papilla surgical approach with allograft plus platelet-rich fibrin in the treatment of intraosseous defects in stage III periodontitis patients. Such innovative procedures of surgeries and research with allografts are boosting the market's growth.

Regional Analysis

By region, the global soft tissue allografts market is segmented into North America, Asia Pacific, Europe, Middle East & Africa, and South America

North America accounted for the highest market share and is estimated to grow at a CAGR of 6.2% during the forecast period. The United States market growth is primarily driven by factors such as the increasing prevalence of diabetic foot ulcers, better healthcare awareness programs for diabetes, and an increasing number of surgical procedures on the anterior cruciate ligament (ACL). According to the study "Anterior Cruciate Ligament Knee Injuries," published in 2020, the anterior cruciate ligament (ACL) is frequently injured among athletes and trauma victims. 100,000 to 200,000 ACL ruptures occur per year in the U.S. alone. This increase in bone and soft tissue demand is expected to drive the overall market. As per American Burn Association(ABA) National Burn repository 2019 report, flame burns were the primary cause of the majority of burn injuries accounting for 41% in the United States, followed by scalds attributing to 31% of the total burn injuries. The injuries are majorly related to flame burns, whereas scald injuries are predominant in children less than five years of age. The American Diabetes Federation estimates that 463 million persons worldwide have diabetes, which will rise to 700 million by 2045. Thus increasing incidences of fire and road accidents and diabetes leading to foot ulcers have increased demand for soft tissue allografts.

Europe is the second largest region. It is estimated to reach a predicted value of USD 1600 million by 2030, registering a CAGR of 7.3%. In France, there is an increasing trend of tissue repair and reconstruction surgeries, likely to drive the market's growth. Allograft procedures have become standard procedures found to be performed in orthopedic, trauma, and dental surgery. The number of allograft surgeries is constantly growing. According to the study "Update on the supply and use of allografts in locomotor system pathologies in France," published in 2018, it has been found that allografts are increasingly used in orthopedic surgeries in France. Therefore, it was found that nineteen tissue banks were found to be located. Each tissue bank had its specificities and specialization. This helps in increasing the demand for soft tissue allografts. Hence with the increasing geriatric population, there is an increasing prevalence of diabetes, and the rising geriatric population is increasing the demand for soft tissue allografts in the region. Hence such factors are anticipated to boost the market growth over the forecast period.

The Asia Pacific is the third largest region. In China, some of the factors responsible for the soft tissue allografts market growth are the growing cases of orthopedics and dentistry related to aging and the increasing demand for soft tissue allografts in athletics and other sports. The demand for soft tissue allografts in treating diseases will rise as the older population is projected to grow in the coming years and is more susceptible to joint and dental issues. According to a research study by YanSi et al., published in Oral Diseases 2019, the study results found that in rheumatoid arthritis patients, the periodontal disease condition is worse, especially dental and gingival status. Therefore, Chinese rheumatoid arthritis patients show higher odds of periodontal disease and need medical therapy that boosts the market growth.

Segmental Analysis

The global soft tissue allografts market is segmented by type, application, end-user, and region.

By type, the global soft tissue allografts market is segmented into cartilage, tendon allograft, meniscus allograft, dental allograft, and other types. The cartilage allograft segment accounted for the largest market share and is estimated to grow at a CAGR of 6.5% during the forecast period. The critical elements in orthopedic surgery treatments like joint repair are cartilage allografts. Treatment for chondral and osteochondral diseases typically involves cartilage transplantation, most frequently in the knee. These procedures can help patients with joint cartilage pathology live better lives and reduce their symptoms. The launch of CartiMax viable cartilage allograft by MTF Biologics in March 2019 added to the company's product line. CarMax is a cartilage allograft that resembles putty and is created to treat knee, foot, and ankle defects quickly. The market for cartilage allografts is therefore anticipated to experience significant growth throughout the projected period due to the causes mentioned above.

By application, the global soft tissue allografts market is segmented into orthopedics, dentistry, wound care, and other applications. The orthopedic segment accounted for the largest market share and is estimated to grow at a CAGR of 6.2% during the forecast period. Orthopedic surgeons now frequently employ allografts to treat musculoskeletal disorders, including osteochondral abnormalities in the glenohumeral joint and meniscal deficits in young athletes. For example, according to a study by M. Kloppenburg et al., published in Osteoarthritis and Cartilage Journal 2020, osteoarthritis is a prevalent rheumatic musculoskeletal condition that afflicted around 303 million people worldwide in 2017. Any joint can be affected, although the hands, knee, hip, and spine are most frequently affected. Osteoarthritis has a significant effect on each patient, causing pain and impairment, as well as on society, which is anticipated to increase demand in the near future.

By end user, the global soft tissue allografts market is segmented into hospitals, aesthetic centers, orthopedic clinics, dental clinics, and other end users. The hospital segment accounted for the highest market share and is estimated to grow at a CAGR of 7.2% during the forecast period. The hospital segment is expected to grow because of an increase in the number of hospitals equipped to perform procedures related to soft tissue allografts. According to the American Hospital Association (2021), there were 6,090 active US hospitals in 2019, which increased from 5,534 active hospitals in 2016. The increasing number of active hospitals is responsible for the rising number of surgeries being performed, that ultimately drives the overall market. 

Recent Developments

• September 2022 - AbbVie (NYSE: ABBV) revealed the spectrum of new data from studies of risankizumab (SKYRIZI®) in Crohn's disease and upadacitinib (RINVOQ®) in ulcerative colitis and Crohn's disease that will be presented as live presentations and e-Posters at the United European Gastroenterology (UEG) Week 2022, October 8-11 in Vienna and online. AbbVie is presenting 17 abstracts across a broad range of studies in inflammatory bowel disease (IBD).
• September 2022 - AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CMHP) adopted a positive opinion recommending the approval of risankizumab (SKYRIZI®, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) for the treatment of adults with moderately to severely active Crohn's illness who have had an inadequate response, lost response or were intolerant to conventional or biologic therapy.